“`html
TLDR:
- Terumo launches Terumo Ventures, a $75m CVC arm targeting medtech startups.
- Main focus areas include cardiovascular disease treatment, chronic disease treatment, and digital technologies.
Terumo, a Japanese medical equipment multinational, has established a corporate venture capital arm called Terumo Ventures with a $75 million investment plan over the next five years. The CVC unit, part of Terumo Americas Holding, will specifically target medical technology startups, focusing on areas such as cardiovascular disease treatment, chronic disease treatment, and digital technologies. While this is the first time Terumo has set up its own CVC fund, the company has been involved in healthcare-focused VC funds in the US and China since 2013.
In 2019, Terumo had made limited partner commitments to two US-based VC firms, Treo Ventures and Catalyst Health Ventures, providing $25 million for each fund. The launch of Terumo Ventures follows a trend of pharmaceutical companies increasing their CVC arms, with Taiho boosting the capital of its CVC and incubation arm to $32 million in Japan. This move aligns with Terumo’s strategic focus on innovation and partnership with startups in the medtech sector.
“`
